On the 28th of December, Orbimed Advisors sold 455 thousand Alpine Immune Sciences, Inc. (NASDAQ:) shares for $7 million at an average price of $15.44 per share.
Shares of Alpine Immune Sciences, Inc. are down -18.65% since the transaction.
Orbimed Advisors’s holding in Alpine Immune Sciences, Inc. decreased to about 3.2 million shares with the transaction.
Orbimed Advisors first bought Alpine Immune Sciences, Inc. stock in the third quarter of 2017.
Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:), Merck (MRK), Larimar Therapeutics, Inc. (LRMR) and Mirati Therapeutics Inc (NASDAQ:).
Alpine Immune Sciences, Inc. is its number twenty one position by number of shares and market value among biotechnology & life sciences stocks.
In contrast, Farallon Capital Management and Millennium Management established new holdings in Alpine Immune Sciences, Inc.
Orbimed Advisors has also recently reduced their share in LogicBio Therapeutics, Inc. (LOGC) and Keros Therapeutics, Inc. (KROS).
The total value of the shares sold is estimated at around $40 million.
Orbimed Advisors also reduced their share in Arcutis Biotherapeutics, Inc. (NASDAQ:) and Oric Pharmaceuticals, Inc. (ORIC).
The total value of the shares sold is estimated at around $17 million.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.